Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Onivyde (irinotecan liposomal)
- ublituximab
Interactions between your drugs
irinotecan liposomal ublituximab
Applies to: Onivyde (irinotecan liposomal), ublituximab
Using ublituximab together with irinotecan liposomal may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Of particular concern is an infection known as progressive multifocal leukoencephalopathy (PML), which is a rare but serious viral infection of the brain that may lead to disability and death. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Let your doctor know if you develop signs and symptoms of infection such as fever, chills, sore throat, shortness of breath, blood in phlegm, weight loss; yellow skin, severe fatigue, diarrhea, vomiting, body aches; and pain or burning during urination. Also, seek immediate medical attention if you experience progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, confusion, or changes in thinking, memory, and personality, as these may be early symptoms of PML. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Abraxane
Abraxane is an antineoplastic medication used in the treatment breast cancer. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Erlotinib
Erlotinib (Tarceva) is a type of targeted therapy used to treat pancreatic cancer and non-small ...
Olaparib
Olaparib (Lynparza) is a PARP inhibitor used to treat breast cancer, prostate, ovarian, and ...
Everolimus
Everolimus (Afinitor, Afinitor Disperz, Zortress) belongs to a class of drugs called kinase ...
Gemcitabine
Gemcitabine is used for breast cancer, breast cancer, metastatic, nasopharyngeal carcinoma, non ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.